Results 281 to 290 of about 41,065 (312)
Some of the next articles are maybe not open access.
ChemInform Abstract: Sulfonyl Azoles in the Synthesis of 3‐Functionalized Azole Derivatives
ChemInform, 2016AbstractReview: [111 refs.
PALMIERI, Alessandro, PETRINI, Marino
openaire +4 more sources
Seminars in Respiratory and Critical Care Medicine, 2008
This is a comprehensive, clinically oriented review of the four commercially available triazoles: fluconazole, itraconazole, voriconazole, and posaconazole. Emphasis is placed in pharmacology, drug interactions, adverse events, antifungal activity, and the evolving perspective of their clinical use.
Dimitrios I. Zonios, John E. Bennett
openaire +3 more sources
This is a comprehensive, clinically oriented review of the four commercially available triazoles: fluconazole, itraconazole, voriconazole, and posaconazole. Emphasis is placed in pharmacology, drug interactions, adverse events, antifungal activity, and the evolving perspective of their clinical use.
Dimitrios I. Zonios, John E. Bennett
openaire +3 more sources
The Journal of Infectious Diseases, 1990
The treatment of opportunistic infections in AIDS patients is changing rapidly as new drugs become available and new studies of old drugs are completed. I have tried to use the AIDS commentaries to keep up with these advances. Since fluconazole has just recently been approved by the US Food and Drug Administration, I asked Dr. Robert A.
openaire +3 more sources
The treatment of opportunistic infections in AIDS patients is changing rapidly as new drugs become available and new studies of old drugs are completed. I have tried to use the AIDS commentaries to keep up with these advances. Since fluconazole has just recently been approved by the US Food and Drug Administration, I asked Dr. Robert A.
openaire +3 more sources
Expert Opinion on Emerging Drugs, 2005
Systemic and superficial fungal infections have progressively emerged over the past few decades as an increasing cause of human disease, especially in the immunocompromised host. Control of fungal disease has proved difficult because few risk factors are potentially preventable; the population at highest risk for fungal disease, the immunocompromised ...
Anne Chen, Jack D. Sobel
openaire +3 more sources
Systemic and superficial fungal infections have progressively emerged over the past few decades as an increasing cause of human disease, especially in the immunocompromised host. Control of fungal disease has proved difficult because few risk factors are potentially preventable; the population at highest risk for fungal disease, the immunocompromised ...
Anne Chen, Jack D. Sobel
openaire +3 more sources
Acta Crystallographica Section C Crystal Structure Communications, 2000
The structure analyses of racemic 3-chloro-1-(4-morpholino-5-nitroimidazol-1-yl)propan-2-ol, C(10)H(15)ClN(4)O(4), (II), and 3-chloro-1-(5-morpholino-4-nitroimidazol-1-yl)propan-2-ol, C(10)H(15)ClN(4)O(4), (III), have been undertaken in order to determine the position of the morpholine residue in these two isomers.
Andrzej Gzella +2 more
openaire +3 more sources
The structure analyses of racemic 3-chloro-1-(4-morpholino-5-nitroimidazol-1-yl)propan-2-ol, C(10)H(15)ClN(4)O(4), (II), and 3-chloro-1-(5-morpholino-4-nitroimidazol-1-yl)propan-2-ol, C(10)H(15)ClN(4)O(4), (III), have been undertaken in order to determine the position of the morpholine residue in these two isomers.
Andrzej Gzella +2 more
openaire +3 more sources
Reaction of tetracyanoquinodimethane with azoles [PDF]
Chemistry of Heterocyclic Compounds, 1976 The reaction of tetracyanoquinodimethane (TCQD) with azoles was studied. It was found that products of 1,6 addition to the quinoid system of TCQD are formed with pyrrole, indole, and their methyl derivatives. The addition products split out HCN under the influence of UV light to give deeply colored products of replacement of one nitrile group in TCQD ...
E. V. Getmanova +3 more
openaire +1 more source
Journal of Infection, 2015
Azole-resistance in Aspergillus fumigatus is emerging and is becoming an increasing problem in the management of aspergillosis. Two types of development of resistance have been described; resistance acquired during azole treatment in an individual patient and through environmental exposure to fungicides. The main molecular mechanism of azole resistance
openaire +3 more sources
Azole-resistance in Aspergillus fumigatus is emerging and is becoming an increasing problem in the management of aspergillosis. Two types of development of resistance have been described; resistance acquired during azole treatment in an individual patient and through environmental exposure to fungicides. The main molecular mechanism of azole resistance
openaire +3 more sources
Synthesis of N-(α-Fluorovinyl)azoles by the Reaction of Difluoroalkenes with Azoles
The Journal of Organic Chemistry, 2014AbstractA slight excess (1.2 equiv.) of difluoroalkene reacts with various N‐heterocycles to afford monosubstituted (E)‐configurated products.
Xuxue Zhang +3 more
openaire +4 more sources
Trifluoromethanesulfonamide derivatives of azoles
Journal of Fluorine Chemistry, 2011Abstract Trifluoromethanesulfonamide-substituted azoles were synthesized by the reaction of 5-aminotetrazole, 3-amino-1,2,4-triazole and 3,5-diamine-1,2,4-triazole with trifluoromethanesulfonyl fluoride to prepare only monosubstituted compounds. All the compounds were fully characterized using ( 1 H, 19 F, 13 C) NMR spectroscopy, mass spectrometry (
Jean'ne M. Shreeve, Sonali Garg
openaire +3 more sources
Clinical Infectious Diseases, 1992
The discovery of the antifungal activity of azole compounds represented an important therapeutic advance. Miconazole, ketoconazole, and fluconazole are currently commercially available, and itraconazole has undergone extensive clinical evaluation. Because of its limited activity and toxicity, miconazole has been replaced by newer agents.
openaire +3 more sources
The discovery of the antifungal activity of azole compounds represented an important therapeutic advance. Miconazole, ketoconazole, and fluconazole are currently commercially available, and itraconazole has undergone extensive clinical evaluation. Because of its limited activity and toxicity, miconazole has been replaced by newer agents.
openaire +3 more sources